Measuring altered disposition of xenobiotics in experimental models of liver disease

Curr Protoc Toxicol. 2012 May:Chapter 23:Unit 23.1.. doi: 10.1002/0471140856.tx2301s52.

Abstract

Understanding the metabolic pathway and excretion mechanisms governing the disposition of a compound is essential to the safe use of pharmaceutical agents. Because the liver is the primary organ responsible for the metabolism and elimination of xenobiotics, chronic liver disease can have a significant effect on the disposition of many xenobiotics due to changes in the expression or function of drug metabolizing enzymes and transporters. Liver disease can result in increased retention of a xenobiotic within the body, causing greater exposure of the individual to a potentially harmful compound, which may lead to toxicity. On the other hand, liver disease may also up-regulate the elimination processes of a xenobiotic, accelerating its removal from the body. With regard to a pharmaceutical agent, enhanced elimination may result in a decreased pharmacologic effect. Such alterations may necessitate dosage adjustments to achieve the desired therapeutic outcome.

MeSH terms

  • Animals
  • Bile / metabolism
  • Disease Models, Animal*
  • Fatty Liver / metabolism*
  • Metabolic Clearance Rate
  • Mice
  • Mice, Inbred C57BL
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Distribution
  • Xenobiotics / blood
  • Xenobiotics / pharmacokinetics*

Substances

  • Xenobiotics